Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). The analysis, based on... [Read Article]
Print Friendly, PDF & Email

Quizartinib can prolong OS in rel/ref, FLT3-ITD AML

Print Friendly, PDF & Email


The 23rd Congress of the European Hematology Association
Phase 3 results suggest the FLT3 inhibitor quizartinib can prolong overall survival (OS) in patients with relapsed/refractory, FLT3-ITD acute myeloid leukemia (AML). In the QuANTUM-R study, patients who received single-agent quizartinib had a significantly longer median OS than patients who received salvage chemotherapy. There was a... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during 2018 ASCO Annual Meeting
Photo by © ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of... [Read Article]
Print Friendly, PDF & Email

Ivosidenib active in R/R IDH1-mutated AML patients

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall response rate of 42% in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML) and IDH1 mutation, according to investigators. In addition, overall survival... [Read Article]
Print Friendly, PDF & Email

Dasatinib outcomes similar to imatinib in pediatric Ph+ ALL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Dasatinib used during induction and consolidation in the Children’s Oncology Group (COG) AALL0622 trial provided early response rates for children with Ph-positive (Ph+) acute lymphoblastic leukemia (ALL), according to investigators. But the early response rates did not improve event-free survival (EFS) compared to the use of consolidation... [Read Article]
Print Friendly, PDF & Email

FDA approves first biosimilar pegfilgrastim

Print Friendly, PDF & Email


Vials and a syringe
The US Food and Drug Association (FDA) has approved pegfilgrastim-jmdb (Fulphila™) as the first biosimilar to Neulasta®. The agents reduce the risk of infection or the duration of febrile neutropenia in patients treated with immunosuppressive chemotherapy for non-myeloid hematologic malignancies. The FDA approved Fulphila based on evidence that included extensive... [Read Article]
Print Friendly, PDF & Email

VF incidence increases significantly in kids after ALL treatment

Print Friendly, PDF & Email


Lumbar vertebrae (shown in red)
Credit: Anatomography
A 6-year prospective study from the Canadian STOPP investigators revealed that following treatment for acute lymphoblastic leukemia (ALL), approximately 1 out of 3 children experiences vertebral fractures (VF) and 1 out of 5 children shows non-VF. Glucocorticoid use and vertebral fractures at diagnosis emerged as significant... [Read Article]
Print Friendly, PDF & Email